XML 34 R25.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Notes to the consolidated financial statements (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2022
Notes to the consolidated financial statements |
Schedule of revenue from contract with customers recognized | ​
​ | ​ | ​ | ​ | ​
​ |  | Six months ended June 30
​ | ​ | 2021 |  | 2022
​ | ​ | EUR k | ​ | EUR k
Belgium | ​ | ​ | ​ | ​
GSK | ​ | 29,335 | ​ | 43,041
Germany |  | ​ | ​ | ​
Boehringer Ingelheim |  | 2,051 | ​ | —
Switzerland |  |  | ​ | ​
CRISPR |  | 169 | ​ | 586
Netherlands | ​ | ​ | ​ | ​
Genmab | ​ | 870 | ​ | 892
Total |  | 32,425 | ​ | 44,519
Summary of upfront payments and related revenues recognized | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Upfront and | ​ | Upfront and | ​ | Revenue recognized from
​ | ​ | ​ | ​ | milestones payments included | ​ | milestones payments included | ​ | upfront and milestones payments
​ | ​ | ​ | ​ | in contract | ​ | in contract | ​ | for six months ended
​ |  | Upfront payments |  | liabilities at |  | liabilities at |  | June 30,
Customer | ​ | June 30, 2022 | ​ | December 31, 2021 | ​ | June 30, 2022 | ​ | 2021 |  | 2022
​ | ​ | ​ | ​ | (EUR k) | ​ | (EUR k) | ​ | (EUR k)
GSK |  | EUR 205,000k (EUR 10,000k milestone payment included) |  | 135,494 |  | 114,725 |  | 24,631 | ​ | 30,769
CRISPR |  | USD 3,000k (EUR 2,524k)* |  | 1,239 |  | 1,084 |  | 155 | ​ | 155
Boehringer Ingelheim |  | EUR 30,000k |  | — |  | — |  | 2,051 | ​ | —
Genmab |  | USD 10,000k (EUR 8,937k)* |  | 5,362 |  | 4,469 |  | 894 | ​ | 894
Total |  | ​ |  | 142,095 |  | 120,278 |  | 27,731 | ​ | 31,818
* Translated at the currency exchange rate prevailing on the transaction date.
Schedule of contract balances | ​
​ | ​ | ​ | ​ | ​
​ |  | December 31, |  | June 30,
​ | ​ | 2021 | ​ | 2022
​ | ​ | EUR k | ​ | EUR k
Trade receivables |  | 18,504 |  | 13,341
Contract liabilities |  | 142,095 |  | 120,278
Schedule of cost of sales, selling and distribution expenses, research and development expenses and general and administrative expenses | The cost of sales consists of the following: ​
​ | ​ | ​ | ​ | ​
​ |  | Six months ended June 30,
​ | ​ | 2021 |  | 2022
​ | ​ | EUR k | ​ | EUR k
Personnel |  | (9,390) | ​ | (13,869)
Materials |  | (2,912) | ​ | (36,883)
Third-party services |  | (31,388) | ​ | (19,516)
Maintenance and lease |  | (2,543) | ​ | (1,150)
Amortization and depreciation |  | (1,594) | ​ | (8,326)
Other |  | (5,329) | ​ | (169)
Total |  | (53,156) | ​ | (79,913)
Selling and distribution expenses consist of the following: ​
​ | ​ | ​ | ​ | ​
​ |  | Six months ended June 30,
​ | ​ | 2021 |  | 2022
​ | ​ | EUR k | ​ | EUR k
Personnel |  | (664) | ​ | (560)
Amortization and depreciation |  | (43) | ​ | (32)
Other |  | (322) | ​ | (227)
Total |  | (1,029) | ​ | (819)
R&D expenses consists of the following: ​
​ | ​ | ​ | ​ | ​
​ |  | Six months ended June 30,
​ | ​ | 2021 |  | 2022
​ | ​ | EUR k | ​ | EUR k
Materials |  | (5,928) | ​ | (23,419)
Personnel |  | (15,219) | ​ | (14,849)
Amortization and depreciation |  | (1,795) | ​ | (2,119)
Patents and fees to register a legal right |  | (1,413) | ​ | (1,354)
Third-party services |  | (210,590) | ​ | 21,053
Maintenance and lease |  | (142) | ​ | (464)
Other |  | (1,180) | ​ | (1,270)
Total |  | (236,267) | ​ | (22,422)
General and administrative expenses consist of the following: ​
​ | ​ | ​ | ​ | ​
​ | ​ | Six months ended June 30,
​ | ​ | 2021 |  | 2022
​ |  | EUR k |  | EUR k
Personnel |  | (19,362) | ​ | (18,971)
Maintenance and lease |  | (1,230) | ​ | (2,704)
Third-party services |  | (18,785) | ​ | (12,796)
Legal and other professional services |  | (3,491) | ​ | (5,320)
Amortization and depreciation |  | (3,325) | ​ | (6,091)
Other |  | (4,458) | ​ | (5,796)
Total |  | (50,651) | ​ | (51,678)
Schedule of other operating income | ​
​ | ​ | ​ | ​ | ​
​ | ​ | Six months ended June 30,
​ | ​ | 2021 |  | 2022
​ |  | EUR k |  | EUR k
Compensation for CMO transfer | ​ | — | ​ | 33,961
Reimbursement claim | ​ | — | ​ | 610
Sale of equipment | ​ | — | ​ | 310
Grants and other cost reimbursements from government agencies and similar bodies | ​ | 45,110 | ​ | 104
Other |  | 124 | ​ | 222
Total |  | 45,234 | ​ | 35,207

X
- References No definition available. + Details
Name: | cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract
Namespace Prefix: | cvac_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of detailed information about upfront payments and related revenues recognized. + References No definition available. + Details
Name: | cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory
Namespace Prefix: | cvac_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2021-01-01 -Paragraph 114 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of expenses by nature. [Refer: Expenses, by nature] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfExpensesByNatureExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of other operating income. [Refer: Other operating income (expense)] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2021-01-01 -Paragraph 118 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_118&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration